Screener
Gyre Therapeutics, Inc. GYRE Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $588K— | $740K-21.4% | —— | —— | —— | ||
| $32.93M+7.8% | $29.11M-2.1% | $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | ||
| $1.95M+19.6% | $2.21M+91.9% | $1.23M+37.2% | $1.74M+48.1% | $1.63M+69.9% | ||
| $30.99M+7.1% | $26.9M-5.9% | $21.29M+0.6% | $35.45M+32.8% | $28.94M+18.0% | ||
| 94.1%-0.6pp | 92.4%-3.7pp | 94.6%-1.4pp | 95.3%-0.5pp | 94.7%-1.6pp | ||
| —— | —— | $6.74M+118% | $4.82M+29.7% | $2.36M-14.8% | ||
| $15.03M-2.0% | $13.75M-9.5% | $14.14M+30.4% | $23.82M+41.3% | $15.33M+11.9% | ||
| $8.92M+107% | $7.87M+8.1% | $7.22M+45.7% | $6.7M+22.6% | $4.32M+13.0% | ||
| $34.45M+45.8% | $43.47M+35.9% | $31.87M+61.1% | $37.08M+36.3% | $23.64M+11.2% | ||
| -$1.52M-122% | -$14.36M-541% | -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | ||
| -4.6%-27.3pp | -49.3%-41.8pp | -41.5%-51.8pp | 0.3%-2.1pp | 22.7%+6.0pp | ||
| -$498K-169% | -$943K-93.2% | $29K-72.9% | -$2.19M-34.3% | $727K+1,069% | ||
| -$1.75M-123% | -$14.43M-816% | -$9.24M-299% | $3.75M+385% | $7.63M+94.1% | ||
| $733K-56.7% | -$164K-125% | $621K-31.1% | $1.3M+540% | $1.69M+57.6% | ||
| -$4.05M-212% | -$11.66M-471% | -$8.69M-422% | $763K— | $3.61M+221% | ||
| -12.3%-24.1pp | -40.1%-33.2pp | -38.6%-50.8pp | 2.1%+2.1pp | 11.8%+7.4pp | ||
| -$0.04-233% | -$0.12-300% | -$0.10— | $0.02— | $0.03+200% | ||
| -$1.05M-115% | -$12.88M-946% | -$8.68M-409% | $774K-31.3% | $7.21M+54.0% | ||
| -3.2%-26.8pp | -44.3%-40.1pp | -38.6%-51.3pp | 2.1%-2.0pp | 23.6%+5.2pp | ||
| -$1.52M-122% | -$14.36M-541% | -$9.36M-512% | $118K-82.3% | $6.93M+63.6% |
FAQ
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $121.8M in revenue over the trailing twelve months, up 10.5% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $23.6M over the trailing twelve months, a -19.4% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 94.1% and operating margin is -20.6%, with a -19.4% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.24.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
